Level C· Early human research exploring benefitsProspective StudyPubMedOpen access

Treatment of canine pancreatitis using membrane-free stem cell extract and its anti-inflammatory effect.

Choi Y., Lee M., Kim B., Kim Y.

Prospective Study on Chronic Inflammation, published in Front Vet Sci (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Front Vet Sci (2025)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
40524736
PMCID
PMC12168361
DOI
10.3389/fvets.2025.1590703

Abstract (original English)

Canine pancreatitis can lead to the digestion of nearby organs, and if untreated, it can develop into peritonitis. Widely used treatment as of now for acute pancreatitis (AP), however, largely depends on supportive treatment such as fluid therapy, antibiotics, and sufficient nutrient intake. Membrane-free stem cell extract (MF-STEM) is a protein mixture and other bioactive molecules derived from human adipose stem cells. MF-STEM is known for its anti-inflammatory and regenerative effects. This study was a vehicle-controlled clinical study. One hundred and forty-five canine pancreatitis patients with pancreatitis participated in this study with owners' consent. Following the owners' consent, 63 dogs received MF-STEM cell therapy with conventional therapy, and 82 dogs received conventional therapy. All participants had their cPL and CRP measured to evaluate their clinical progression. At the time of discharge, the survival rate in the MF-STEM cell therapy group survived (survival 92% and mortality 8%) more than the control group (survival 46% and mortality 54%). The authors suppose that MF-STEM cell increases survival of pancreatitis patients by modulating inflammatory cytokines. There were no side effects observed, such as allergic reactions and hypersensitivity reactions.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research